Table 3 Pathways associated to our pan-cancer signature genes
| Â | Â | Â | q-value | q-value |
|---|---|---|---|---|
source | pathway name | p-value | (FDR) | (Bonferroni) |
WikiPathways | Photodynamic therapy-induced | \(1.05 \times 10^{-7}\) | \(1.82 \times 10^{-4}\) | \(1.82 \times 10^{-4}\) |
| Â | HIF-1 survival signaling | Â | Â | Â |
WikiPathways | Androgen receptor signaling | \(4.43 \times 10^{-5}\) | \(1.54 \times 10^{-2}\) | \(7.67 \times 10^{-2}\) |
PID | Direct p53 effectors | \(1.93 \times 10^{-5}\) | \(1.67 \times 10^{-2}\) | \(3.34 \times 10^{-2}\) |
REACTOME | Extracellular matrix organization | \(3.97 \times 10^{-5}\) | \(1.73 \times 10^{-2}\) | \(6.90 \times 10^{-2}\) |
PID | HIF-2-alpha transcription factor network | \(3.19 \times 10^{-5}\) | \(1.85 \times 10^{-2}\) | \(5.54 \times 10^{-2}\) |
PID | Beta1 integrin cell surface interactions | \(7.02 \times 10^{-5}\) | \(2.03 \times 10^{-2}\) | \(1.22 \times 10^{-1}\) |
PID | Beta3 integrin cell surface interactions | \(9.88 \times 10^{-5}\) | \(2.45 \times 10^{-2}\) | \(1.72 \times 10^{-1 }\) |
WikiPathways | Primary Focal Segmental | \(1.15 \times 10^{-4}\) | \(2.48 \times 10^{-2}\) | \(1.99 \times 10^{-1}\) |
| Â | Glomerulosclerosis FSGS | Â | Â | Â |
PID | Alpha9 beta1 integrin signaling events | \(1.31 \times 10^{-4}\) | \(2.52 \times 10^{-2}\) | \(2.27 \times 10^{-1}\) |
REACTOME | ECM proteoglycans | \(2.01 \times 10^{-4}\) | \(3.18 \times 10^{-2}\) | \(3.50 \times 10^{-1}\) |
KEGG | MicroRNAs in cancer | \(1.90 \times 10^{-4}\) | \(3.30 \times 10^{-2}\) | \(3.30 \times 10^{-1}\) |
ACSN2 | MOMP_REGULATION | \(3.22 \times 10^{-4}\) | \(4.30 \times 10^{-2}\) | \(5.59 \times 10^{-1}\) |
WikiPathways | Mammary gland development pathway | \(3.12 \times 10^{-4}\) | \(4.51 \times 10^{-2}\) | \(5.42 \times 10^{-1}\) |
|  | – Puberty (Stage 2 of 4) |  |  |  |